GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 7174-7182

  Sonpavde, Guru ^a,b   Thompson, Timothy C ^b   Jain, Rajul K ^a   Ayala, Gustavo E ^a   Kurosaka, Shinji ^b   Edamura, Kohei ^b   Tabata, Ken Ichi ^b   Ren, Chengzhen ^b   Goltsov, Alexei A ^b   Mims, Martha P ^a   Hayes, Teresa G ^a,b   Ittmann, Michael M ^b   Wheeler, Thomas M ^a   Gee, Adrian ^a   Miles, Brian J ^a   Kadmon, Dov ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GAMMA INTERFERON; GLIOMA PATHOGENESIS RELATED PROTEIN 1; HLA DR ANTIGEN; INTERLEUKIN 12; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER REGRESSION; CANCER STAGING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG ADMINISTRATION ROUTE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSURIA; FEASIBILITY STUDY; FLOW CYTOMETRY; FLU LIKE SYNDROME; GENE EXPRESSION; GLEASON SCORE; GLIOMA PATHOGENESIS RELATED PROTEIN 1 GENE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; INTRAPROSTATIC DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SIDE EFFECT; TRANSRECTAL ULTRASONOGRAPHY; TUMOR SUPPRESSOR GENE; UPREGULATION; URINARY TRACT INFECTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS PARTICLE;

ADENOVIRIDAE; AGED; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, SUPPRESSOR; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK;

EID: 81255143331     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1899     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. (Pubitemid 39315318)
4. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
7. Sonpavde G, Palapattu GS. Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. Expert Rev Anticancer Ther 2010;10:439-50.
8. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-6; discussion 6-7.
9. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180:565-70; discussion 70.
10. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007;110:1248-54. (Pubitemid 47435595)
11. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40. (Pubitemid 41003711)
12. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 2009;27:4986-93.
13. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97: 1287-96. (Pubitemid 41535369)
14. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 2004;10: 2587-93. (Pubitemid 38509130)
15. Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 2003;10: 755-63. (Pubitemid 37243796)
16. Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001;12:883-92. (Pubitemid 32681853)
17. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, et al. Loss of p53 function leads to metastasis in ras+ myc-initiated mouse prostate cancer. Oncogene 1995;10:869-79.
18. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995;1:1111-8.
19. Yang G, Stapleton AM, Wheeler TM, Truong LD, Timme TL, Scardino PT, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res 1996;2:399-401. (Pubitemid 26075643)
20. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, et al. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 2002;22:3345-57. (Pubitemid 34453976)
21. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 2003;14:91-101. (Pubitemid 36418814)
22. Naruishi K, Timme TL, Kusaka N, Fujita T, Yang G, Goltsov A, et al. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther 2006;13:658-63. (Pubitemid 44264470)
23. Ren C, Li L, Yang G, Timme TL, Goltsov A, Ji X, et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 2004;64:969-76. (Pubitemid 38176899)
24. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A, et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004;64:6082-90. (Pubitemid 39129408)